



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>Applicants:</b>	Gregory Collier, et al.	<b>Examiner:</b>	Christine J. Saoud
<b>Serial No:</b>	10/039,050	<b>Art Unit:</b>	1647
<b>Filed:</b>	December 31, 2001	<b>Docket:</b>	12785
<b>For:</b>	NOVEL GENES AND THEIR USE IN THE MODULATION OF OBESITY, DIABETES AND ENERGY IMBALANCE		

**Confirmation No.:** 2282

Commissioner for Patents  
Alexandria, VA 22313-1450

**DECLARATION PURSUANT TO 37 C.F.R. §1.131**

Sir:

We, Gregory Collier, Paul Z. Zimmet, Kenneth R. Walder, Kelly F. Windmill and  
Janine S. McMillan, hereby declare that:

1. We are co-inventors named in the above-identified application.
2. We have been advised by our legal representative that U.S. Patent Publication 2002/0055627 to Rosen et al. ("the '627 application") has been cited by the Examiner as a prior art reference under §102(e) in respect to the above-identified application. The '627 application was filed on August 10, 2001, as a continuation of PCT/US00/05883, filed on March 8, 2000, which claims priority from Provisional Application 60/124,270, filed on March 12, 1999.

BEST AVAILABLE COPY

3. One embodiment disclosed and claimed in the present application is directed to an isolated nucleic acid molecule encoding for a protein which comprises the amino acid sequence set forth in SEQ ID NO: 6, also referred to in the application as "human B55" protein. One such nucleic acid molecule, also disclosed and claimed in the present application, is the nucleic acid molecule having a nucleotide sequence set forth in SEQ ID NO: 5.


4. We isolated the human B55 nucleic acid molecule having the sequence as set forth in SEQ ID NO: 5 in Australia prior to March 12, 1999, the alleged priority date of the '627 application.

5. As evidence of the isolation of the human B55 molecule having SEQ ID NO: 5, we provide herewith Exhibit A. Exhibit A is a copy of the facsimile transmission sent by Professor Greg Collier (a co-inventor) to Dr. Neville McCarthy on a date prior to March 12, 1999. The date has been masked in the preparation of the photocopies contained in Exhibit A. The facsimile transmission was understood to be a confidential communication.


6. The transmission consists of a cover page and six pages of a Progress Report with respect to "Band 55", the designation for B55. The nucleotide sequence of SEQ ID NO: 5 was disclosed at the top of page 3 of the Progress Report, under the heading "Band 55 mRNA HUMAN SEQUENCE".

7. We declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that those statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: \_\_\_\_\_



For Walker



\_\_\_\_\_

\_\_\_\_\_

Dated: \_\_\_\_\_

16/12/05

Dated: \_\_\_\_\_

16/12/05

Dated: \_\_\_\_\_

16/12/05

Dated: \_\_\_\_\_

Dated: \_\_\_\_\_

By: \_\_\_\_\_

Dated: \_\_\_\_\_

\_\_\_\_\_

Dated: \_\_\_\_\_

\_\_\_\_\_

Dated: \_\_\_\_\_

\_\_\_\_\_

Dated: \_\_\_\_\_

*Paul Zimmet*

Dated: December 16, 2005

By: \_\_\_\_\_

Dated: \_\_\_\_\_

\_\_\_\_\_

Dated: \_\_\_\_\_

\_\_\_\_\_

Dated: \_\_\_\_\_

\_\_\_\_\_

Dated: \_\_\_\_\_

J. McMillan

Dated: 16<sup>th</sup> December, 2005

METABOLIC RESEARCH UNIT – School of Nutrition & Public Health  
Deakin University, Pigdons Road, Waurin Ponds, Victoria, Australia  
POSTAL: Deakin University, Geelong, Victoria, Australia, 3217.

FACSIMILE  
TELEPHONE

Domestic: (03) 522 72170  
Domestic: (03) 522 72547

International: + 61 3 5227 2170  
International: + 61 3 5227 2547



## FACSIMILE COVER SHEET

Date:

DATE MASKED

No. of pages (incl this page): 7

To:

Dr Neville McCarthy

Facsimile No: 03 9234 1190

From:

Prof Greg Collier

Facsimile No: (03) 5227 2191

Message:

Dear Neville

As discussed please find following a summary of the progress we have made with Band 55.

Cheers

A handwritten signature in black ink, appearing to be 'Greg Collier', written over a series of horizontal lines.

Greg

FAXED

## BAND 55

### *Sequence and Structure*

The band 55 mRNA is 1155 nucleotides in length and does not match any known genes in the public database, but has homology with expressed sequence tags (ESTs) from a variety of tissues. The predicted open reading frame results in a protein of 189 amino acids in *Psammomys obesus*. Mouse, rat and human sequences were deduced from ESTs (3 rat, 5 mouse and 8 human sequences were used). The mouse and rat protein were found to be 188 amino acids long and were 91% and 93% homologous to the *Psammomys obesus* sequence, respectively. The human protein was found to be 187 amino acids long and was 82% homologous to the *Psammomys obesus* sequence. There were no nucleotide or amino acid differences found between lean, obese or diabetic *Psammomys obesus*. Band 55 is located on chromosome 15 in humans from 15q26.1 to 15qter and on chromosome 7 in mice.

Band 55 is predicted to have one transmembrane region at residues 37 to 53 with a C-terminal cytoplasmic tail. The tail contains a coiled coil region from amino acids 79 to 117. Coiled coil regions are found predominantly in some structural proteins and in a class of DNA-binding proteins in which the coiled coil region is called a leucine zipper domain. The coiled coil in band 55 is only about 40 residues long, much shorter than the very long coils found in many fibrous proteins such as myosin and keratin. It also does not appear to be a leucine zipper which are characterized by a leucine every seventh residue. There are 5 leucines, all of which are at  $\alpha$  or  $d$  sites but they do not line up down one side of the helix. Coiled coils are found within many other proteins, however, and mediate a wide variety of functions.

A dileucine motif was also found in the cytoplasmic tail. Dileucine motifs have been shown to be involved in trans Golgi sorting, lysosomal targeting and internalization of a number of proteins. The insulin receptor,  $\beta$ 2-adrenergic receptor and the glucose transporter GLUT4 all have a dileucine motif which is involved in internalization.

Band 55 has one potential PEST sequence (RPQEEDGPGPSTSSSVTR). Proteins with intracellular half-lives of less than two hours are found to contain regions rich in proline, glutamic acid, serine and threonine (P, E, S and T). These so called PEST regions are generally flanked by clusters of positively charged amino acids. The ProtParam computer program instability index also classified the protein as unstable.

## BAND 55 mRNA SEQUENCE

GTCGTTGGTTTCGGCGGCCATGGAGAGCGCAGAGGAGCCTCTGCCCGCGCGGCCGCGCTGGAGACCGAGG  
GCCTGAGGTTCCCTGCACGTCACAGTGGGCTCCCTGCTGGCCAGCTATGGCTGGTACGTCCTCTTCAGCTGC  
ATCCTTCTCTACATTGTCATCCAGAAGCTCTCCGTCCGATTGAGGGTTTGGAGGCAGAGGCAGCTGGACCA  
GGCTGACGCTGTTCTGGAACCTGATGCTGTTGTTAAGCGACAAGAGGCTTTAGCCGCTGCTCGTTTGAGAA  
TGCAGGAAGATCTAAATGCCCAAGTTGAAAAGCATAAGGAAAACTAAGACAGCTTGAAGAAGAAAAAGG  
AGACAGAAGATTGAAATGTGGGACAGCATGCAAGAAGGCAGAAAGTTACAGAAGAAATCCAGGAAGGCCCTCA  
GGAAGAAGATGGTCTGGACCTTCTACTTCATCATCTGTCAACCGCAAAGGAAAAATCTGACAAAAAGCCTT  
TGAGGGGAAATGGTTATAACCCCTCTGACGGGTGAAGGGGGTGAACCTGCGCCTGGAGACCTGGACGCAGG  
GGCCCATCATCTGGTGGATGAAGCTAAGACCCCTGTTAGTGTGCTTTGACATTAGCAAGGTGAACCCCTTA  
ACCTCAACTCAGTTGCCTTACGCACACTTTCACAGTGAAGTACCAAGGAGAGGTGGGGCTTATTTCCATT  
CGTAGCTACCTGTATTCTAAGGGCTTTGGTCAGTGTGAGCTATGGACATTGTCATTAGGTCATATTTCTACT  
TAGACAACAGTCATTGATTTTCATGGCTACTTGCTAGTTGATAGGTTAAAGGCCCTCTCGCTGTTTAGCAAC  
TTCATAAAGGAGGCCAGTGATGATCCTTTGGGGTAGAAGTCCTTGCTGACAGGATGGTCTCTGTGACAGG  
ATGCGTTCAATGATGTCTTCCTTATAAATGGTGAGCCACCAGTGAGGATTACTGATGTGCACAGTTGATG  
GGGTTTGCTTCTGTATATTTATTTTATGTACAGAAATTTGCAAAAAAATAAAAGTAACATTTTTAGC  
ATCTTTATTAACTCAAGGAAATTTCTGTTGTGAGCTTGACTTTGTCTATCAGACATTAAACAGCTTTTTAT  
CATTAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

## BAND 55 PROTEIN SEQUENCE (189 aa)

MESAEELPARPALETEGLRFLHVTVGSLASYGWVLFSCILLYIVIQLSVRLRVLRQRQLDQADAVLE  
PDVVKRQEALAAARLRMQEDLNAQVEKHKEKLRLQLEEKRRQKIEMWDSMQEGRSYRRNPGRPQEDGPG  
PSTSSSVTRKGKSDKKPLRGNGYNPLTGECCGTCAWRPGRGPSSGG



## BAND 55 mRNA HUMAN SEQUENCE

CAGGGCTGGGCGGCGGCGGCGGCGGCGGTCATGGAACGCCAAGAGGAGTCTCTGTCCGCGCGGCGGCGGCT  
GGAGACCGAGGGGCTGCGCTTCCTGCACACCACGGTGGGCTCCCTGCTGGCCACCTATGGCTGGTACATCG  
TCTTCAGCTGCATCCTTCTCTACGTGGTCTTTCAGAAGCTTTCGCGCCGGCTAAGAGCCTTGAGGCAGAGG  
CAGCTGGACCGAGCTGCGGCTGCTGTGGAACCTGATGTTGTTGTTAAACGACAAGAAGCTTTAGCAGCTGC  
TCGACTGAAAATGCAAGAAGAACTAAATGCGCAAGTTGAAAAGCATAAGGAAAACTGAAACAACCTTGAAG  
AAGAAAAAAGGAGACAGAAGATTGAAATGTGGGACAGCATGCAAGAAGGAAAAAGTTACAAAGGAAATGCA  
AAGAAGCCCCAGGAGGAAGACAGTCCTGGGCCTTCCACTTCATCTGTCTGAAACGGAAATCGGACAGAAA  
GCTTTGCGGGGAGGAGGTTATAACCCGTTGTCTGGTGAAGGAGGCGGAGCTTGCTCCTGGAGACCTGGAC  
GCAGAGGCCCGTCATCTGGCGGATGAGGCTAAGAATCTTGTTAGTGTCACTTTTGACATTAGCAAGATGAA  
CCCTTAACCCCTCGATTCAATTGCCTTACGCACGCTTTTCACAGTGACTAGCCAAGGGGAGGTGGGGTTGAT  
TTCTGTTCCCTAACTACACCTGCATATGTCAGGGCTCCAGTCAGCAAAAGGTATAGATGTTGCCTCTAGGCA  
TGAGGTCATTGGTCACATTCCTACTTGGAGACAGTGATTGCATTCAATTGATTTTATGGTTAATTGCTAGTTG  
GTAGGTAAAGGCCCTCTAGATGATTAGCAATCTTGATAAAAGAGGCCTAGTAATGTTCTTTTGAGGTTAGAA  
ATCCTTGCTGCTAGGACAGTCTCTGTGACAGGTTGCGTTGAATGATGTCTTCCTTATCAATGGTGAGCCCA  
CCAGTGAGGATTACTGATGTGGACAGTTGATGGGGTTTGTCTGTATATTTATTTTATGTACAGAACTT  
TGTAACAAACGAACTATTTAAAAACAAGAATAACATTTTATAGCATCTTTATTCAAGGAGATTTATGGACT  
TCAATTTGTCTATCAAACATTAAATAGCTTTTTTATTAC

## BAND 55 PROTEIN HUMAN SEQUENCE (187 aa)

MERQEESLSARPALETEGLRFLHTTVGSLLATYGWYIVFSCILLYVVFQKLSARLRALRQRQLDRAAAAVE  
PDVVVKRQEALAAARLKMQEELNAQVEKHKEKLKQLEEEKRRQKIEMWDSMQEGKSYKGNAKKPQEEDSPG  
PSTSSVLKRKSDRKPLRGGGYNPLSGEGG?CSWRPGRRGPSGG

Suggested that we assume the unknown amino acids at positions 172 and 173 as G and T respectively,  
based on the sand rat sequence.

# Band 55 protein

	10	20	30	40	50
ISR	MESAEELPARPALETEGLRFLHVTVGSLASYGWVLFSCILLYIVIQK				
MOUSE	-DRD---S-@---S-*-----I-----R				
RAT	---S-----S-----I---V-----				
HUMAN	--RQ--S-S-----T-----T---IV-----V-F--				

	60	70	80	90	100
ISR	LSVRLRALRQRQLDQADAVLEPDAVVKRQEALAAARLRMQEDLNAQVEKH				
MOUSE	--L-----ET---V-----				
RAT	--L-----E---V-----				
HUMAN	--A-----R-A-AV---V-----K---E-----				

	110	120	130	140	150
ISR	KEKLRQLEEEKRRQKIEMWDSMQEGRSYRRNPGRPQEEDGPGPSTSSSVT				
MOUSE	-----K-S-----/---I				
RAT	-----K-----/---I				
HUMAN	---K-----#--KG-AKK---S---/---L				





	160	170	180	189
ISR	RKGKSDKKPLRGNGYNPLTGEGGGTCAWRPGRRGPSGG			
MOUSE	P-----G-----S-----			
RAT	P-----G-----			
HUMAN	/-R--R---G---S---??-S-----			

@=R or S  
 \*=R or Q  
 # = R or K  
 A = mixture of A and V

## Gene Expression

Band 55 gene expression was found to be significantly upregulated in the liver of fasted compared to fed animals ( $p < 0.0001$ ). This was evident in groups A, B and C, and the difference appeared more pronounced in obese, diabetic animals. A similar trend was observed in the adipose tissue, with higher levels of expression after fasting ( $p < 0.05$ ). This was found in groups B and C only, with the greatest difference in C animals.

In the fed state, there was a significant correlation between liver gene expression and blood triglyceride levels ( $p < 0.01$ ).



### *Cell culture studies*

*Glucose and insulin effects* – HepG2 cells (grown in high glucose media) were treated with different concentrations of insulin (5nM, 50nM and 500nM) for 4 or 24 hours. 4 hours of insulin treatment in high glucose media caused a dose-dependent decrease in band 55 expression. Treatment with 5nM insulin caused a 25% reduction in band 55 expression whilst 50nM and 500nM insulin caused a 42%-43% reduction in expression. The decrease in band 55 expression with insulin treatment was statistically significant at 50nM and 500nM (ANOVA,  $p < 0.05$ ) when compared to the untreated controls. A similar result was observed after 24 hours treatment with insulin (5nM, 50nM, 500nM) in high glucose media. 5nM insulin for 24 hours caused a 23% reduction in band 55 gene expression whilst 50nM and 500nM insulin produced a 62%-63% reduction in expression. Although, band 55 expression was decreased with 24 hours of insulin treatment, it was not statistically significant due to the variability within the control (no insulin) group of cells.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☒ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**